Animalcare Share Discussion Threads

[p1nkfish] 16/4/2024 18:01

Some decent volume through today at 213-214p.
Helping to clear a seller. 14x average daily volume of the past 3 months.
Highest volume since 7th Nov 2023.

[p1nkfish] 11/4/2024 15:30

DYOR etc but looking good to me for anyone with a 3-5 year timeframe.
IMC soon.

a) Attractive return
b) enhanced commercial licensing arrangement achieved - wider reach
c) Could be DECHRA, KANE BIOTECH + ANIMALCARE collaboration - CEO reads as keen on this element


"Chief Executive Officer of Animalcare, Jenny Winter said: "This transaction offers value for Animalcare on several levels. Not only have we secured an attractive return on our equity investment in STEM that adds to our investment firepower, we have gained enhanced commercial licensing rights that grant us more options to reach pet owners in these key markets. Further into the future, I'm also excited about the potential to accelerate development of new biofilm-targeting products by combining the knowledge and resources of all three parties."

[p1nkfish] 11/4/2024 15:23

Potentially another $5M approx USD from exit of equity in STEM whilst ANCR allowed distribution access to all channels in Europe and UK. DECHRA taking it.

Just found the analysts presentation on the web, page 16, the have approx 7 products or companies in discussion out of more than 450 to begin with. Homing in on target(s) and now have the cash and credit facilities to pull the trigger(s).



I like the look of the way they have a plan and focused on executing it.

[p1nkfish] 09/4/2024 11:37

IMC mid April for the results, presentation for analysts today will be on the website soon.
Net cash now, a good cushion.

[p1nkfish] 16/3/2024 12:27

A pullback before heading higher imho.
Was fortunate enough to be accumulating for a while.
Patience needed.
GLA, dyor etc.

[masurenguy] 16/3/2024 08:58

Looks like they got a very good price (£24.9m) for Identicare (annual sales just circa £3m) and the disposal has also enabled them to restructure the balance sheet with a post completition net cash position of circa £27m. Would doubt that the CMA investigation would have any significant concerns for them since the issue relates to Vet mark up margins rather than ANCR wholesale prices. This company seems to be under most retail investors radar screens but circa 70% of the shares are owned by around half a dozen institutions so this looks worth further research and investigation.

[1c3479z] 13/3/2024 16:17

have to agree that ANCR least likely to be affected by the CMA enquiry, just putting it out as a conjecture, if the whole vet industry is to be brought to heal by the authorities. Not trying to scare at all as ANCR is a family holding, albeit small, sadly, in comparison with my own holding in CVSG which is much more in the firing line.

[p1nkfish] 13/3/2024 15:13

Exactly. Trying to scare.
Need more vets = more competition = more demand = good for all except monopoly vets.
ANCR should not be damaged but more likely see more demand.

[wjccghcc] 13/3/2024 14:34

No. The CMA was complaining that some vets add a big mark up on the wholesale price vs the internet pharmacies.

[p1nkfish] 13/3/2024 14:28

Trying to scare?
Ignore and carry on.

[1c3479z] 13/3/2024 13:22

CMA mounting a big enquiry, will that impact the price of veterinary drugs in general including wholesale?

[p1nkfish] 05/3/2024 09:34

A monthly close above 229.5p and there is a chance it runs a while, no doubt some set backs along the way, but likely heading a decent amount higher thereafter. Dyor etc.

[p1nkfish] 28/2/2024 13:00

Need more Vets to increase competition and that should also increase demand for AnimalCare products.

[p1nkfish] 28/2/2024 12:13

More to do with Vets services and practices I believe.

[1c3479z] 28/2/2024 11:44

Will the CMA enquiry cause them any trouble if they've to reduce their product prices?

[p1nkfish] 28/2/2024 08:51

Was buying this whilst no one else was interested. Should have bought more. Can become a lovely little business spinning off cash and with some growth thrown in - assuming they allocate the cash wisely, which I think they will. CEO seems sensible.

[p1nkfish] 28/2/2024 08:09

If we were lucky enough to close the month over about 229.5p the complexion would change considerably. Perhaps a pullback afterwards but then march onwards and upwards imho. Dyor etc.

[p1nkfish] 28/2/2024 08:07

There's always the risk the capital isn't allocated wisely but the CEO appears sensible overall with a keen focus on cash conversion and stable growth. My target (I don't have a timescale) is £4+. Dyor etc, I'm often wrong.

Do suspect they have some targets for the cash lined-up.

[p1nkfish] 28/2/2024 07:52

From the latest preliminary financial update: "The Group ended the financial year in a net cash position, pre IFRS16 leases, of £1.7 million, (31 December 2022: £2.4 million debt). This very strong financial platform enables the pursuit of inorganic and organic opportunities that support the Group's long-term growth strategy."

Today after Identicare sale: "........cash consideration of £24.9m (the "Consideration") payable upon completion of this sale........Upon receipt of the Consideration and after fees associated with the transaction, the Company's net cash is expected to be around £27.0m."

About £116M market cap with net cash of £27M and £74.4M revenue last year with strong cash conversion, lose about £3M revenue from Identicare (haven't checked if profit contribution, certainly was growing & probably a decent margin).

Now more focussed. See if it garners interest in the next few weeks prior to results on 9th April.

Still a lovely and quiet PBB.

[1c3479z] 28/2/2024 07:33

Excellent if they use the money wisely,

[p1nkfish] 28/2/2024 07:31

Indenticare disposal and now a stronger balance sheet loaded up with cash.
I wasn't expecting a change this quickly.
Good news overall and now focus on core business growth.

"Jenny Winter, Chief Executive Officer commented: "I'm very proud to see what we have achieved with Identicare in recent years. Today's decision to crystallise the value from the sale is the logical next step, significantly strengthening our balance sheet and giving us additional financial flexibility and firepower as we concentrate on growing our pharmaceutical-focused animal health business.""

[p1nkfish] 08/2/2024 16:39

May pullback but looking like a breakout and still lovely and quiet.

[p1nkfish] 07/2/2024 12:26

May not be this week but getting there.